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In the light of challenging financial times affecting 
healthcare across the UK, the 2010 Gastroenterology 
Symposium focused on presenting the latest best-
practice evidence to effectively and safely manage 
patients with common gastrointestinal (GI) conditions 
while minimising unnecessary cost. 
SeSSion 1 How do i manage?
Professor Chris Probert (Professor of Gastroenterology, 
Bristol Royal Infirmary) outlined the clinical and financial 
problem of Clostridium difficile-associated diarrhoea 
(CDAD). Approximately 50,000 cases are diagnosed in 
England and Wales each year, with an annual cost to the 
European Union of €3 billion. Patients over 65 years are 
ten times more likely to develop CDAD due to increased 
hospitalisation, reduced immune response, higher prevalence 
of co-morbidity and greater prescription of antibiotics.1 
Central to reducing CDAD’s health and cost burden is an 
early diagnosis and institution of effective treatment. 
Faecal enzyme-linked immunosorbent assay is currently 
the most common method of diagnosing CDAD but may 
miss as many as 20% of cases. In the future, gas 
chromatography mass spectrometry may provide a rapid, 
ward-based diagnosis method. Steps to improve CDAD 
prevention include the development of strict antibiotic-
prescribing policies to avoid precipitating medications 
such as cephalosporins and fluoroquinolones, avoiding 
unnecessary hospital admission and discontinuing proton 
pump inhibitor therapy in high-risk patients. 
Lower GI bleeding is a common presenting problem 
experienced by up to one in seven adults. Miss Sarah 
Mills (Consultant Colorectal Surgeon, Wansbeck General 
Hospital, Northumberland) explained that although the 
vast majority will have no significant underlying pathology, 
colorectal cancer is the third most common malignancy 
in the UK and clinicians must consider each patient’s 
risk.  The concurrence of a change in bowel habit without 
anal symptoms (e.g. discomfort, prolapse or itching) 
should increase the clinical suspicion of cancer.2 Multiple 
endoscopic and radiological tests exist to investigate 
lower GI bleeding, but the importance of a digital rectal 
examination at first clinic visit should not be underestimated. 
Haemorrhoids are a common cause of benign rectal 
bleeding. Most cases can be managed without specialist 
referral through dietary advice and strain avoidance. 
Professor Chris Day (Pro Vice Chancellor, Faculty of 
Medical Sciences, Newcastle University) described the 
spectrum of non-alcoholic fatty liver disease from 
asymptomatic deranged liver function tests to liver 
cirrhosis, leading to hepatocellular cancer or the need for 
transplantation. Non-alcoholic fatty liver disease may be 
part of the metabolic syndrome, and is strongly associated 
with obesity, hypertension, diabetes and dyslipidaemia. Its 
prevalence may be more than 40% in the background 
population.3 The condition is an independent risk factor 
for cardiovascular disease, and is more likely to progress 
to end-stage liver disease in the presence of active hepatic 
inflammation/fibrosis. The key to treatment is lifestyle 
modification to lose weight and improve fitness. Potential 
medical therapies include vitamin E, pioglitazone for 
patients with type 2 diabetes mellitus and angiotensin-2 
receptor blockers for those with hypertension.
SeSSion 2 enSuring patient Safety
In the past ten years, biologics have revolutionised the 
management of complex inflammatory bowel disease 
(IBD). Despite their proven efficacy as powerful immuno-
suppressants, infliximab and adalimumab are not without 
complication risks. Professor Jack Satsangi (Professor of 
Gastroenterology, University of Edinburgh) discussed safety 
considerations such as potential side effects of sepsis, 
demyelination and malignancy, including hepatosplenic T-cell 
lymphoma and lung cancer.  As IBD is a condition with 
associated morbidity but not mortality, the individual risk of 
a potentially life-threatening complication must be 
considered. Clinicians must be sure to exclude pelvic sepsis, 
screen for tuberculosis and consider alternative treatment 
strategies including surgery, where appropriate. Special 
care should be taken in older patients and in smokers.
Despite the emergence of biological therapy, steroids 
remain an important and commonly used therapeutic 
agent in gastroenterology. However, prolonged use can 
lead to osteoporosis. Professor Juliet Compston (Professor 
of Bone Medicine, University of Cambridge) explained 
that fracture risk increases with higher dosage steroids 
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and longer duration of prescription. Bone protection 
must therefore be considered early in those who have 
received, or are going to receive, glucocorticoids for 
longer than three months. Knowledge of the ten-year 
probability of fracture is useful when planning treatment 
and can be calculated at www.shef.ac.uk/FRAX. Lifestyle 
measures to manage or avoid osteoporosis include 
maintaining adequate nutrition (calcium, vitamin D and 
normal body weight), avoiding smoking or excess alcohol 
and improved exercise. Pharmacological interventions in 
men and post-menopausal women include bisphosphonates 
or recombinant parathyroid hormone. In pre-menopausal 
women, calcium supplementation when dietary intake is 
low may be a more appropriate intervention.
SeSSion 3 gaStrointeStinal tHerapeuticS, 
avoiding waSte
Dr Miles Parkes (Consultant Gastroenterologist, 
Addenbrooke’s Hospital, Cambridge) reviewed the 
evidence base for using mesalazine in Crohn’s disease. 
Whether given orally or rectally, mesalazine coats, and is 
metabolised by, intestinal epithelial cells, so the theoretical 
ability to penetrate transmural inflammation associated 
with Crohn’s disease is questionable. Indeed, the current 
European Crohn’s and Colitis Organisation consensus 
guidance on Crohn’s disease states that ‘mesalazine 
should be considered clinically no more effective than 
placebo for active ileal or colonic Crohn’s disease’ and 
‘5ASAs are not recommended for maintenance of 
medically induced remission in Crohn’s disease’.4 In these 
scenarios, clinicians should consider slow withdrawal for 
patients already receiving mesalazine. There may be a role 
for mesalazine in preventing recurrence in post-operative 
disease or as a chemopreventative agent in colorectal 
cancer associated with colonic Crohn’s, but at present 
there is a lack of conclusive evidence to support this.
 
Dr Bjorn Rembacken (Consultant Endoscopist, Leeds 
Teaching Hospitals) outlined situations in which modern 
endoscopy may improve outcomes in pathologies that 
have historically been treated by surgery. Endoscopic 
mucosal resection (EMR) can be used in the stomach, 
colon, rectum or oesophagus to remove areas of 
mucosal dysplasia or even malignancy, provided it is well 
differentiated, superficial and has no lymphovascular 
invasion. Dr Rembacken also described the emerging 
treatment of endoscopic submucosal dissection which 
has the advantage of being able to remove large, non-
pedunculated dysplastic or malignant polyps en bloc. 
Early results suggest that a complete removal of lesions 
may be possible in 85% of cases, but the perforation rate 
may be as high as 3.5–12% (vs 1.3% in EMR).5
Returning to the topic of patient safety, Mr Paul Philip 
(Deputy Chief Executive, General Medical Council 
[GMC]), explained the necessity for the GMC to introduce 
revalidation to ensure that all clinicians remain up to date 
and fit to practice. Revalidation will be a continual, 
formative process of assessing performance, ideally 
through existing appraisal frameworks and according to 
Good Medical Practice guidelines.   A key outcome is to 
provide doctors with a non-threatening opportunity to 
reflect on the strengths and weaknesses in their practice. 
SeSSion 4 new developmentS
The past decade has seen major advances in the 
understanding of gene–environmental interactions that 
may lead to IBD. Dr Charlie Lees (Consultant Gastro-
enterologist, Western General Hospital, Edinburgh) 
explained that a total of 98 genes have now been identified 
as associated with either Crohn’s disease, ulcerative colitis 
or both. These discoveries have greatly informed our 
understanding of disease pathogenesis. Perhaps in the future 
we may identify new immune targets or understand how 
best to use existing therapeutic agents by predicting response 
or complication risk according to a patient’s genotype.
The symposium closed with an update on developments 
in the treatment of viral hepatitis from Dr Andrew Holt 
(Consultant Hepatologist, Queen Elizabeth Hospital, 
Birmingham) – please see his review on page 59.
take-Home meSSage
The UK is faced with a need to reduce public spending 
but has an obligation to facilitate the highest possible 
standards of patient care and safety. To achieve this, 
reducing disease burden through lifestyle modification and 
the restructuring of primary and secondary care services 
should be encouraged. Importantly, investment in trans-
lational research and the development of new technologies 
must not be neglected as they hold the potential to treat 
illness more quickly and safely in future. 
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